This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Avanir Pharmaceuticals' Presents At Deutsche Bank Securities Annual Health Care Conference (Transcript)

Avanir Pharmaceuticals, Inc. (AVNR)

Deutsche Bank Securities Annual Health Care Conference Call

May 8, 2012 2:50 pm ET

Executives

Keith A. Katkin – President and Chief Executive Officer

Analysts

Robyn Karnauskas – Deutsche Bank Securities, Inc.

Presentation



Robyn Karnauskas – Deutsche Bank Securities, Inc.

Good afternoon, thanks for joining us this afternoon. Next, we have Avanir. And speaking for Avanir, we have Keith Katkin, the President and CEO. For those of you listening on the webcast, if you have questions, we’d like to ask them anonymously, you can go to our website [viorn.com/hz] and ask questions anonymously we will read them here.

With that, I will turn it over to Keith.

Keith A. Katkin

Thanks, Robyn. And good afternoon everyone. Thank you for joining us for the Avanir corporate presentation. I would like to start with the forward-looking statements, as I will be making statements that are forward-looking in nature. I’d encourage everyone to visit our publically available documents on the SEC website or on the Avanir website as well.

So Avanir is a specialty biopharmaceutical company focused on CNS therapies. And our lead product is NUEDEXTA, as the first and only FDA approved therapy for the treatment of pseudobulbar affect. Pseudobulbar affect is a very large market with a high unmet medical need, and I go into a little more detail on PBA later in the presentation.

And importantly from a mechanistic perspective, NUEDEXTA is an NMDA receptor antagonist and a sigma-1 agonist, a very well known and well understood mechanism of action, which we believe supports the potential use of NUEDEXTA in a number of other additional indications.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,080.61 +42.64 0.24%
S&P 500 2,111.89 +2.97 0.14%
NASDAQ 5,056.73 -3.5160 -0.07%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs